NEW YORK (360Dx) – Theradiag today announced a deal to provide its Lisa Tracker kits for monitoring Biogen's Flixabi (infliximab) biosimilar.
Biogen will now be able to supply Lisa Tracker monitoring kits in the competitive tenders in which it participates in France, where the therapeutic firm has marketed two biosimilar drugs, including Flixabi, an autoimmune disease treatment. Today's deal also allows Biogen to offer Lisa Tracker in other European countries.
Theradiag will be Biogen's preferred supplier of infliximab monitoring kits. The French company will implement the kits in laboratories, provide training on how to use the kits, and follow up with clinicians on requests concerning monitoring, Theradiag said.
Financial and other terms of the deal were not disclosed.
"This agreement with Biogen advances our strategy of developing together with pharmaceutical groups and provides further evidence of their interest in our monitoring kits," Theradiag CEO Michel Finance said in a statement.